Physician profile
Christopher Sprando
NPI 1700892684
$4,753.70
in general payments reported to CMS, 2019-2025
30 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.47 · 2020: $114 · 2021: $243 · 2022: $351 · 2023: $1,719 · 2024: $1,894 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,853 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,853.35 |
| Education | $129.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,736.75 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $604.61 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $475.98 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.58 | 2021-2025 | Jardiance |
| Pfizer INC. | $251.96 | 2021-2024 | |
| Shield Therapeutics INC | $218.67 | 2023-2024 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $203.22 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $201.37 | 2019-2024 | Airsupra, Lokelma, Farxiga |
| Abbvie INC. | $129.10 | 2023-2024 | Vraylar, Ubrelvy |
| Exact Sciences Corporation | $86.33 | 2023-2024 | Cologuard Collection Kit |
| Inari Medical, INC. | $79.92 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.80 | 2023-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $68.75 | 2023-2024 | Nuedexta, Rexulti |
| Boston Scientific Corporation | $53.80 | 2022 | |
| Amgen INC. | $49.57 | 2023-2024 | Repatha, Otezla |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $44.94 | 2023-2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $23.63 | 2024 | Gvoke Hypopen |
| Medtronic, INC. | $23.23 | 2024 | Inpen Smart Insulin Delivery System |
| Dynavax Technologies Corporation | $20.18 | 2019-2021 | |
| Amarin Pharma, INC. | $17.68 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.79 | 2022 | |
| Sumitomo Pharma America, INC. | $14.87 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $14.56 | 2023 | |
| Merck Sharp & Dohme LLC | $14.39 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.35 | 2024 | Eliquis |
| Currax Pharmaceuticals LLC | $13.90 | 2023 | Contrave, Onzetra Xsail |
| Allergan, INC. | $13.53 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.47 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.43 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sprando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.